SG&A Efficiency Analysis: Comparing Viking Therapeutics, Inc. and MorphoSys AG

SG&A Efficiency: A Tale of Two Biotech Companies

In the competitive world of biotechnology, managing operational costs is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of MorphoSys AG and Viking Therapeutics, Inc. from 2014 to 2023. Over this period, MorphoSys AG's SG&A expenses surged by over 850%, peaking in 2021. In contrast, Viking Therapeutics, Inc. maintained a more conservative growth, with expenses increasing by approximately 290%.

Key Insights

• 2014-2017: Both companies kept expenses relatively stable, with MorphoSys AG averaging around $10 million annually, while Viking Therapeutics, Inc. hovered around $5 million.
• 2018-2020: MorphoSys AG's expenses skyrocketed, reaching $159 million in 2020, a stark contrast to Viking's $10 million.
• 2021-2023: MorphoSys AG's expenses slightly declined, while Viking's expenses more than tripled, indicating a strategic shift.

This data highlights the contrasting financial strategies of these two biotech firms, offering valuable insights for investors and industry analysts.